​

Immunocore (IMCR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

IMCR Stock Forecast

Immunocore (IMCR) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $29.50, with a high of $35.00 and a low of $24.00. This represents a 3.84% increase from the last price of $28.41.

$20 $30 $40 $50 $60 $70 High: $35 Avg: $29.5 Low: $24 Last Closed Price: $28.41

IMCR Stock Rating

Immunocore stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (76.92%), 3 Hold (23.08%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 13 3 10 0 Strong Sell Sell Hold Buy Strong Buy

IMCR Price Target Upside V Benchmarks

TypeNameUpside
StockImmunocore3.84%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts-18
Avg Price Target-$35.00$67.63
Last Closing Price$28.41$28.41$28.41
Upside/Downside-23.20%138.05%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 255731-16
Mar, 255731-16
Feb, 255721-15
Jan, 255721-15
Dec, 246721-16
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 07, 2025Morgan Stanley$35.00$29.8017.45%23.20%
Oct 24, 2024David DaiUBS$24.00$32.02-25.05%-15.52%
Sep 16, 2024Justin KimOppenheimer$89.00$33.05169.29%213.27%
Sep 12, 2024Graig SuvannavejhMizuho Securities$72.00$33.44115.31%153.43%
Aug 28, 2024Patrick TrucchioH.C. Wainwright$100.00$35.71180.03%251.99%
Aug 09, 2024Peter LawsonBarclays$66.00$37.9274.05%132.31%
May 13, 2024Graig SuvannavejhMizuho Securities$88.00$57.2553.71%209.75%
May 09, 2024Bill MaughanCanaccord Genuity$67.00$61.329.26%135.83%
Dec 15, 2022Rajan SharmaGoldman Sachs$80.00$59.4234.63%181.59%
Sep 09, 2022Michael YeeJefferies$68.00$44.0354.44%139.35%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 24, 2024OppenheimerUnderperformUnderperformhold
Oct 24, 2024H.C. WainwrightBuyBuyhold
Oct 24, 2024UBSSellinitialise
Oct 07, 2024NeedhamUnderperformUnderperformhold
Oct 07, 2024GuggenheimNeutraldowngrade
Sep 16, 2024OppenheimerOutperformOutperformhold
Sep 16, 2024Cowen & Co.BuyBuyhold
Aug 28, 2024OppenheimerBuyBuyhold
Aug 28, 2024H.C. WainwrightBuyBuyhold
Aug 09, 2024H.C. WainwrightUnderperformUnderperformhold

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 $1 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.33$-3.10$-0.90$-1.13$-1.02----
Avg Forecast$-6.48$-2.97$-0.33$-0.78$-0.68$-1.14$-1.60$-0.74$0.61
High Forecast$-5.92$-2.72$-0.30$-0.58$-0.46$-0.14$-0.45$0.69$0.74
Low Forecast$-6.92$-3.17$-0.41$-0.94$-1.07$-1.78$-3.04$-2.37$0.54
Surprise %-64.04%4.38%172.73%44.87%50.00%----

Revenue Forecast

$0 $150M $300M $450M $600M $750M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$30.11M$26.52M$143.74M$249.43M$310.20M----
Avg Forecast$37.62M$34.68M$168.66M$247.63M$314.59M$354.46M$379.07M$443.05M$628.29M
High Forecast$39.56M$36.47M$201.25M$266.94M$318.27M$383.57M$380.94M$454.05M$730.34M
Low Forecast$35.14M$32.39M$156.95M$219.56M$313.06M$328.98M$377.20M$432.06M$571.66M
Surprise %-19.95%-23.53%-14.77%0.72%-1.40%----

Net Income Forecast

$-350M $-270M $-190M $-110M $-30M $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-74.09M$-131.52M$-41.22M$-55.29M$-51.09M----
Avg Forecast$-316.83M$-145.26M$-16.15M$-37.16M$-47.05M$-72.08M$-98.18M$-63.59M$30.04M
High Forecast$-289.67M$-132.81M$-14.70M$-28.29M$-22.35M$-7.05M$-22.24M$33.96M$36.39M
Low Forecast$-338.10M$-155.01M$-20.21M$-46.02M$-52.51M$-87.01M$-148.86M$-115.75M$26.52M
Surprise %-76.61%-9.46%155.19%48.79%8.59%----

IMCR Forecast FAQ

Is Immunocore stock a buy?

Immunocore stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Immunocore is a favorable investment for most analysts.

What is Immunocore's price target?

Immunocore's price target, set by 13 Wall Street analysts, averages $29.5 over the next 12 months. The price target range spans from $24 at the low end to $35 at the high end, suggesting a potential 3.84% change from the previous closing price of $28.41.

How does Immunocore stock forecast compare to its benchmarks?

Immunocore's stock forecast shows a 3.84% upside, underperforming the average forecast for the healthcare stocks sector (35.25%) and underperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Immunocore over the past three months?

  • April 2025: 31.25% Strong Buy, 43.75% Buy, 18.75% Hold, 6.25% Sell, 0% Strong Sell.
  • March 2025: 31.25% Strong Buy, 43.75% Buy, 18.75% Hold, 6.25% Sell, 0% Strong Sell.
  • February 2025: 33.33% Strong Buy, 46.67% Buy, 13.33% Hold, 6.67% Sell, 0% Strong Sell.

What is Immunocore’s EPS forecast?

Immunocore's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.14, marking a 11.76% increase from the reported $-1.02 in 2024. Estimates for the following years are $-1.6 in 2026, $-0.74 in 2027, and $0.61 in 2028.

What is Immunocore’s revenue forecast?

Immunocore's average annual revenue forecast for its fiscal year ending in December 2025 is $354.46M, reflecting a 14.27% increase from the reported $310.2M in 2024. The forecast for 2026 is $379.07M, followed by $443.05M for 2027, and $628.29M for 2028.

What is Immunocore’s net income forecast?

Immunocore's net income forecast for the fiscal year ending in December 2025 stands at $-72.078M, representing an 41.09% increase from the reported $-51.087M in 2024. Projections indicate $-98.182M in 2026, $-63.587M in 2027, and $30.04M in 2028.